ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,937.34
-0.21%
Dow Jones
43,153.13
-0.16%
US Dollar vs MXN
20.88387
0.23%
Brent Oil
80.805
0.36%
Bitcoin
101,760.79
1.75%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Guardant Health Inc (GH) Cotización

Guardant Health Inc

Guardant Health Inc (GH)

Gamehost Inc
37.31
0.00
(0.00%)
Cerrado 17 Enero 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
Fuera de horario: -
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
37.31
Postura de Compra
36.59
Postura de Venta
37.80
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
15.81 Rango de 52 semanas 39.29
Capitalización de Mercado [m]
4.61B
Precio Anterior
37.31
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,933,897
Acciones en circulación
123,554,612
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-9.62
Beneficio por acción (BPA)
-3.88
turnover
563.95M
Beneficio neto
-479.45M

Acerca de Guardant Health Inc

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Mostrar más

Sector
Medical Laboratories
Industria
Medical Laboratories
Sitio web
www.guardanthealth.com
Sede
Dover, Delaware, USA
Fundado
-
Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was US$37.31. Over the last year, Guardant Health shares have traded in a share price range of US$ 15.81 to US$ 39.29.

Guardant Health currently has 123,554,612 shares in issue. The market capitalisation of Guardant Health is US$4.61 billion. Guardant Health has a price to earnings ratio (PE ratio) of -9.62.

GH Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities

10 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 horas hace
Edgar (US Regulatory)

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and...

19 horas hace
Business Wire

Form 8-K - Current report

13 Enero 2025
Edgar (US Regulatory)

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today...

13 Enero 2025
Business Wire

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin Pilot study by National Cancer...

07 Enero 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

06 Enero 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Enero 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Enero 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Enero 2025
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.461.2483039348736.8539.2934.8220409337.42762419CS
46.6221.570544151230.6939.2929.91191114134.60177312CS
1217.1284.794452699420.1939.2920.14193389731.60107934CS
264.2912.992125984333.0239.2920.14205792329.01597752CS
5214.2261.585101775723.0939.2915.81203923125.9665698CS
156-38.63-50.869107189975.9478.3415.81171460532.57727412CS
260-46.52-55.493260169483.83181.0715.81143471954.0532224CS

GH - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Guardant Health?
El precio actual de las acciones de Guardant Health es US$ 37.31
¿Cuántas acciones de Guardant Health están en circulación?
Guardant Health tiene 123,554,612 acciones en circulación
¿Cuál es la capitalización de mercado de Guardant Health?
La capitalización de mercado de Guardant Health es USD 4.61B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Guardant Health?
Guardant Health ha negociado en un rango de US$ 15.81 a US$ 39.29 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Guardant Health?
El ratio precio/beneficio de Guardant Health es -9.62
¿Cuál es el ratio de efectivo a ventas de Guardant Health?
El ratio de efectivo a ventas de Guardant Health es 8.18
¿Cuál es la moneda de reporte de Guardant Health?
Guardant Health presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Guardant Health?
El último ingresos anual de Guardant Health es USD 563.95M
¿Cuál es el último beneficio anual de Guardant Health?
El último beneficio anual de Guardant Health es USD -479.45M
¿Cuál es la dirección registrada de Guardant Health?
La dirección registrada de Guardant Health es 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
¿Cuál es la dirección del sitio web de Guardant Health?
La dirección del sitio web de Guardant Health es www.guardanthealth.com
¿En qué sector industrial opera Guardant Health?
Guardant Health opera en el sector MEDICAL LABORATORIES

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0

GH Discussion

Ver más
Monksdream Monksdream 4 meses hace
GH buy the dip
👍️0
Monksdream Monksdream 5 meses hace
GH that awful Cathie has been a recent buyer
👍️0
x993231 x993231 6 meses hace
I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.
👍️0
Monksdream Monksdream 8 meses hace
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
👍️0
SubPenny0001 SubPenny0001 8 meses hace
I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
👍️0
Trooperstocks Trooperstocks 8 meses hace
For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 💯 1
Trooperstocks Trooperstocks 8 meses hace
$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
👍️ 1 💪 1
Trooperstocks Trooperstocks 8 meses hace
Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 😍 1
Trooperstocks Trooperstocks 8 meses hace
$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
👍️ 1 💯 1
DewDiligence DewDiligence 2 años hace
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
👍️0
jerseyboy jerseyboy 4 años hace
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
👍️0
jerseyboy jerseyboy 4 años hace
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
👍️0
jerseyboy jerseyboy 4 años hace
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
👍️0
PR_12 PR_12 4 años hace
2-3 years I'm thinking this is @ 3-5X current share price
👍️0

Su Consulta Reciente

NASDAQ
GH
Guardant Health
BIT
P1NMS1
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados